The Evaluation of Animal Models in the Development of Anticancer Agents: From Preclinical to Clinical Tests

被引：2

作者：

Wang, Jie ^{[1
,2
]}

Dong, Haiyan ^{[3
]}

Liu, Jian ^{[1
,2
]}

Zheng, Ning ^{[1
,2
]}

Xie, Xiaodong ^{[1
,2
]}

Jia, Lee ^{[1
,2
,4
]}

机构：

[1] Fuzhou Univ, Canc Metastasis Alert & Prevent Ctr, Fuzhou 350002, Fujian, Peoples R China

[2] Fuzhou Univ, Biopharmaceut Photocatalysis, State Key Lab Photocatalysis Energy & Environm, Fujian Prov Key Lab Canc Metastasis Chemoprevent, Fuzhou 350002, Fujian, Peoples R China

[3] Fujian Med Univ, Sch Basic Med Sci, Fujian Key Lab Translat Res Canc & Neurodegenerat, Inst Translat Med, Fuzhou 350108, Fujian, Peoples R China

[4] Minjiang Univ, Inst Oceanog, Fuzhou 350108, Fujian, Peoples R China

来源：

CURRENT CANCER DRUG TARGETS | 2019年 / 19卷 / 04期

基金：

中国国家自然科学基金;

关键词：

Anticancer drugs; animal toxicological studies; animal models; starting doses; preclinical testing; toxicological studies; TYROSINE KINASE INHIBITOR; PHASE-I; ANTITUMOR-ACTIVITY; DRUG ACTIVITY; PHARMACOKINETICS; CANCER; COMBINATION; TOXICOLOGY; SAFETY; TRIAL;

D O I：

10.2174/1568009618666180817095331

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: One of the main reasons for most of the anticancer drugs to fail in the late preclinical testing and early clinical trials is the differences in drug effects observed from animals and patients, and the challenge has been to find a balance to reduce the inherent differences from species. Objective: Predicting safe starting doses and dosing schedules for human clinical trials is the main purpose of toxicological studies of anticancer drugs. Methods: Relevant information and data were assimilated from manuscripts, congress publications, and online sources. Results: We systematically overview the cons and pros of animal models and briefed the ways to determine human clinical starting doses derived from animal toxicological studies for anticancer drugs. Conclusion: This information helps smart select the suitable predictive model for anti-cancer drugs with the different mechanisms and emphasized the pharmaceutical challenges behind and ahead.

引用

页码：277 / 284

页数：8

共 61 条

[1] Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer [J].